Xencor to co-develop IL-15 therapies with Genentech

Xencor Inc. (NASDAQ:XNCR) will receive $120 million up front in a deal to co-develop its IL-15 cytokine therapeutics, including XmAb24306, with Genentech Inc.

The partners will evaluate

Read the full 266 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE